KPF
KTTA icon

K2 Principal Fund’s Pasithea Therapeutics KTTA Stock Holding History

K2 Principal Fund’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,122
Closed -$181K – 292
2022
Q4 		$181K Sell
14,122
-10,468
-43% -$209K 0.03% 155
2022
Q3 		$620K Hold
24,590
– – 0.07% 142
2022
Q2 		$497K Sell
24,590
-2,910
-11% -$61.9K 0.05% 193
2022
Q1 		$715K Hold
27,500
– – 0.06% 153
2021
Q4 		$973K Buy
+27,500
New +$1.43M 0.06% 185

Other funds holding KTTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

K2 Principal Fund's KTTA Position: Q1 2023 in Review

K2 Principal Fund sold out of Pasithea Therapeutics (KTTA) in Q1 2023, closing a stake of 14,122 shares — an estimated $181K sold.

K2 Principal Fund first reported a position in KTTA in Q4 2021 and held it in 5 quarters. The position peaked at $973K in Q4 2021. 11 funds tracked by Wall St. Rank hold KTTA as of Q1 2023.

  • K2 Principal Fund reported no remaining Pasithea Therapeutics position as of Q1 2023 after selling out during the quarter.
  • K2 Principal Fund sold 14,122 Pasithea Therapeutics shares in Q1 2023, an estimated $181K.
  • K2 Principal Fund first reported a position in Pasithea Therapeutics in Q4 2021 and held it in 5 quarters.
  • K2 Principal Fund's Pasithea Therapeutics position peaked at $973K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2023.

Based on K2 Principal Fund's 13F filing for Q1 2023, filed 11 May 2023.